Replying to Avatar english_news

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

https://financialpost.com/globe-newswire/nervgen-pharma-reports-positive-topline-data-from-the-chronic-cohort-of-its-phase-1b-2a-clinical-trial-evaluating-nvg-291-in-spinal-cord-injury

Avatar
Paula Bogan 7mo ago

Data NVG-291 Chronic Spinal Pharma of from its Topline 1b/2a in Clinical Evaluating Trial Reports the Phase Positive Cord NervGen Injury

https://financialpost.com/globe-newswire/nervgen-pharma-reports-positive-topline-data-from-the-chronic-cohort-of-its-phase-1b-2a-clinical-trial-evaluating-nvg-291-in-spinal-cord-injury Cohort

Reply to this note

Please Login to reply.

Discussion

No replies yet.